PMID- 22640008
OWN - NLM
STAT- MEDLINE
DCOM- 20120921
LR  - 20191210
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 158
IP  - 2
DP  - 2012 Jul
TI  - Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic 
      leukaemia: outcome in a 20-year cohort.
PG  - 174-185
LID - 10.1111/j.1365-2141.2012.09170.x [doi]
AB  - The curative potential of allogeneic haematopoietic stem cell transplant (allo 
      HSCT) in chronic lymphocytic leukaemia CLL is established, with a demonstrated 
      role for graft-versus-leukaemia and less certainty for other factors in 
      determining outcome. The first two decades of CLL patients proceeding to allo 
      HSCT at the Leukaemia/Bone Marrow Transplant Program of British Columbia (n = 49 
      consecutive, 1991-2009) were studied to clarify factors predicting outcome. The 
      donor was related in 29 (59%) and unrelated in 20 (41%). Conditioning was 
      reduced-intensity in 27 (55%) and myeloablative in 22 (45%). Thirty-one of 49 
      patients survive with median follow-up of 5 years (0.2-15). Cumulative incidence 
      of non-relapse mortality; complete remission (CR); clearance of fluorescence in 
      situ hybridization (FISH) abnormality and progression at 10 years was 36%; 69%; 
      55% and 22%. Overall survival (OS) was 63% at 2 years; 55% at 5 years and beyond. 
      Factors predicting OS (P value by log rank <0.05) were: comorbidity index <3, 
      FISH rank (Dohner) and 17p deletion, alemtuzumab pre-HSCT, achievement of CR 
      post-HSCT, donor chimerism >90%, clearance of FISH abnormality post-HSCT and 
      absence of high-grade (3-4) graft-versus-host disease. Results from this 
      province-wide, two-decade cohort demonstrated that a substantial proportion of 
      patients with high-risk CLL become long term disease-free survivors.
CI  - (c) 2012 Blackwell Publishing Ltd.
FAU - Toze, Cynthia L
AU  - Toze CL
AD  - Division of Hematology, Leukemia/BMT Program of British Columbia, Vancouver 
      General Hospital, BC Cancer Agency, University of British Columbia, Vancouver, 
      BC.
FAU - Dalal, Chinmay B
AU  - Dalal CB
AD  - Division of Hematology, Leukemia/BMT Program of British Columbia, Vancouver 
      General Hospital, BC Cancer Agency, University of British Columbia, Vancouver, 
      BC.
FAU - Nevill, Thomas J
AU  - Nevill TJ
AD  - Division of Hematology, Leukemia/BMT Program of British Columbia, Vancouver 
      General Hospital, BC Cancer Agency, University of British Columbia, Vancouver, 
      BC.
FAU - Gillan, Tanya L
AU  - Gillan TL
AD  - Cytogenetics Laboratory, Department of Pathology and Laboratory Medicine, 
      Vancouver General Hospital and University of British Columbia, Vancouver, BC.
FAU - Abou Mourad, Yasser R
AU  - Abou Mourad YR
AD  - Division of Hematology, Leukemia/BMT Program of British Columbia, Vancouver 
      General Hospital, BC Cancer Agency, University of British Columbia, Vancouver, 
      BC.
FAU - Barnett, Michael J
AU  - Barnett MJ
AD  - Division of Hematology, Leukemia/BMT Program of British Columbia, Vancouver 
      General Hospital, BC Cancer Agency, University of British Columbia, Vancouver, 
      BC.
FAU - Broady, Raewyn C
AU  - Broady RC
AD  - Division of Hematology, Leukemia/BMT Program of British Columbia, Vancouver 
      General Hospital, BC Cancer Agency, University of British Columbia, Vancouver, 
      BC.
FAU - Forrest, Donna L
AU  - Forrest DL
AD  - Division of Hematology, Leukemia/BMT Program of British Columbia, Vancouver 
      General Hospital, BC Cancer Agency, University of British Columbia, Vancouver, 
      BC.
FAU - Hogge, Donna E
AU  - Hogge DE
AD  - Division of Hematology, Leukemia/BMT Program of British Columbia, Vancouver 
      General Hospital, BC Cancer Agency, University of British Columbia, Vancouver, 
      BC.
FAU - Nantel, Stephen H
AU  - Nantel SH
AD  - Division of Hematology, Leukemia/BMT Program of British Columbia, Vancouver 
      General Hospital, BC Cancer Agency, University of British Columbia, Vancouver, 
      BC.
FAU - Power, Maryse M
AU  - Power MM
AD  - Division of Hematology, Leukemia/BMT Program of British Columbia, Vancouver 
      General Hospital, BC Cancer Agency, University of British Columbia, Vancouver, 
      BC.
FAU - Song, Kevin W
AU  - Song KW
AD  - Division of Hematology, Leukemia/BMT Program of British Columbia, Vancouver 
      General Hospital, BC Cancer Agency, University of British Columbia, Vancouver, 
      BC.
FAU - Sutherland, Heather J
AU  - Sutherland HJ
AD  - Division of Hematology, Leukemia/BMT Program of British Columbia, Vancouver 
      General Hospital, BC Cancer Agency, University of British Columbia, Vancouver, 
      BC.
FAU - Smith, Clayton A
AU  - Smith CA
AD  - Division of Hematology, Leukemia/BMT Program of British Columbia, Vancouver 
      General Hospital, BC Cancer Agency, University of British Columbia, Vancouver, 
      BC.
FAU - Narayanan, Sujaatha
AU  - Narayanan S
AD  - Division of Hematology, Leukemia/BMT Program of British Columbia, Vancouver 
      General Hospital, BC Cancer Agency, University of British Columbia, Vancouver, 
      BC.
FAU - Young, Sean S
AU  - Young SS
AD  - Cancer Genetics Laboratory, Department of Pathology and Laboratory Medicine, BC 
      Cancer Agency and University of British Columbia, Vancouver, BC.
FAU - Connors, Joseph M
AU  - Connors JM
AD  - Division of Medical Oncology, BC Cancer Agency, Centre for Lymphoid Cancer and 
      University of British Columbia, Vancouver, BC, Canada.
FAU - Shepherd, John D
AU  - Shepherd JD
AD  - Division of Hematology, Leukemia/BMT Program of British Columbia, Vancouver 
      General Hospital, BC Cancer Agency, University of British Columbia, Vancouver, 
      BC.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120529
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
SB  - IM
MH  - Adult
MH  - Aged
MH  - British Columbia/epidemiology
MH  - Cohort Studies
MH  - Comorbidity
MH  - Disease Progression
MH  - Female
MH  - Graft Survival
MH  - Graft vs Host Disease/etiology
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/mortality/*therapy
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Remission Induction
MH  - Transplantation Chimera
MH  - Transplantation Conditioning/methods
MH  - Treatment Outcome
EDAT- 2012/05/30 06:00
MHDA- 2012/09/22 06:00
CRDT- 2012/05/30 06:00
PHST- 2011/11/25 00:00 [received]
PHST- 2012/03/06 00:00 [accepted]
PHST- 2012/05/30 06:00 [entrez]
PHST- 2012/05/30 06:00 [pubmed]
PHST- 2012/09/22 06:00 [medline]
AID - 10.1111/j.1365-2141.2012.09170.x [doi]
PST - ppublish
SO  - Br J Haematol. 2012 Jul;158(2):174-185. doi: 10.1111/j.1365-2141.2012.09170.x. 
      Epub 2012 May 29.